Image source: Brugarolas et al., European Journal of Nuclear Medicine and Molecular Imaging 2022 (CC BY 4.0)

News • Neurological disease marker

Promising new radiotracer for demyelination

Loss of myelin—a protective insulating layer around neurons—is a key contributor to many neurological diseases including multiple sclerosis, traumatic brain and spinal cord injuries, stroke, and dementia; however, there are currently no imaging tests to accurately identify such demyelination and distinguish it from other pathological processes that occur in these conditions.

Investigators at Massachusetts General Hospital (MGH) have now developed such a test: a radioactive demyelination tracer that can be detected by positron emission tomography (PET) scans. They evaluated its use in humans in a study published in the European Journal of Nuclear Medicine and Molecular Imaging. “Having an imaging tool that it is specific to demyelination can help to better understand the contribution of demyelination to different diseases and better monitor a disease or the response to therapy—for example, a remyelinating therapy,” says co–lead author Pedro Brugarolas, PhD, an investigator at the Gordon Center for Imaging at MGH and an assistant professor of radiology at Harvard Medical School.

Photo
The new radiotracer [18F]3F4AP in human subjects. A) Representative whole-body maximum intensity projections of a male and a female participant at different time points. B) Representative brain images of a male and a female participant. C) Averaged time-activity curves of selected organs

Image source: Brugarolas et al., European Journal of Nuclear Medicine and Molecular Imaging 2022 (CC BY 4.0)

In healthy volunteers, Brugarolas and his colleagues investigated the safety of their new PET tracer—called [18F]3F4AP—and looked to see what happens to it after it’s injected intravenously into the body. This was the first time the tracer was given to humans, following studies that were conducted in monkeys. The tracer distributed widely throughout the body, including into the brain, the organ of interest. In addition, the team calculated the volunteers’ radiation exposure from the tracer and they performed basic safety assessments.“ 

As expected for PET tracers, the radiation dose was within normal limits and we didn't see signs that could indicate that the tracer wasn't safe,” says co–lead author Moses Wilks, PhD, an assistant in physics at MGH and an instructor at Harvard Medical School. One unexpected finding was that the tracer cleared from circulation faster than expected, which they plan to investigate further. 

The scientists hope that their findings will help advance research related to diseases involving demyelination. “Giving a new tracer to humans is a big deal as it requires being able to make the tracer in a sterile environment, demonstrating to the U.S. Food and Drug Administration that the trace meets a very strict quality control and getting permission from the agency to administer it to humans,” says senior author Georges El Fakhri, PhD, director of the Gordon Center for Medical Imaging at MGH and a professor of radiology at Harvard Medical School. “Once a tracer has been in humans for the first time and it has been shown to be safe—which is what this study shows—it is easier for other researchers to use it.” 


Source: Massachusetts General Hospital

06.10.2022

Read all latest stories

Related articles

Photo

News • Promising diagnostic tool

Tracing tau tangles against Alzheimer’s

Researchers at Johns Hopkins Medicine have identified in live human brains new radioactive “tracer” molecules that bind to and “light up” tau tangles, a protein associated with a number of…

Photo

News • In-depth view at neurodegeneration

New 3D imaging approach looks into earliest stages of Alzheimer's

Novel 3D imaging could comprehensively characterize a part of the brain that shows perhaps the earliest accumulation of tau protein, an important biomarker for the development of Alzheimer's disease.

Photo

Video • Functional ultrasound microscopy

fULM shows whole brain neuronal activity at the micron scale

Functional ultrasound localization microscopy (fULM) captures the cerebral activity at the micron-scale, opening up major future clinical perspectives for the diagnosis of cerebrovascular pathologies.

Related products

Canon – Alphenix Biplane High Definition Detector

Bi-Plane

Canon – Alphenix Biplane High Definition Detector

Canon Medical Systems Europe B.V.
Canon – Vitrea Advanced Visualization

Reading

Canon – Vitrea Advanced Visualization

Canon Medical Systems Europe B.V.
Siemens Healthineers – Biograph mCT

PET/CT

Siemens Healthineers – Biograph mCT

Siemens Healthineers
Subscribe to Newsletter